Certificate in Cancer Immunotherapy Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers)

Side navigation

Welcome Guest!

Published July 7, 2021

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers), will cover the biological foundation and clinical implementation of cytokines, vaccines and immune cell engagers as immunotherapies for cancer, including adverse event management.

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty

Francesco Marincola, MD

Senior Vice President

Global Head of Cell Therapy Research

Kite, Refuge Biotech

James Gulley, MD, PhD, FACP

Chief of Genitourinary Malignancies Branch

Director, Medical Oncology Service, CCR Office of the Clinical Director

CCR Deputy Director

Center of Cancer Research, National Cancer Institute

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Mechanisms	Define the types and functions of cytokines and chemokines used in cancer immunotherapy. Distinguish among the various types of cancer vaccines. Describe the different types and functions of tumor antigens used in cancer vaccines. Classify the different delivery platforms for cancer vaccines. Describe how personalized cancer vaccines differ from standard cancer vaccines. Identify different methods and routes of administration of immunotherapy agents. Define the types of immunologic adjuvants and their distinct functions in promoting immune responses. Recognize the role of innate immune activators in promoting tumor immunotherapy. Describe the mechanism of action of immune cell engagers. Compare and contrast immune cell engagers with adoptive cellular therapies. Describe potential mechanisms of relapse following immune cell engager therapies.
Clinical Use and Development	Appreciate the historical data on vaccine and cytokine treatment of malignancy. List current clinical indications for vaccines, cytokines, and immune cell engagers in cancer treatment. Explain how immunologic boosting can enhance anti-tumor immunity with vaccines. Describe the role of immunotherapy and vaccines in cancer prevention. Characterize new and emerging vaccines, cytokines and immune cell engagers under clinical investigation. Describe how cytokine levels may be used as prognostic and predictive biomarkers for cancer immunotherapy.
Combination Approaches	Describe how cytokines, vaccines, and immune cell engagers can be combined with other immunotherapy agents to promote T cell recruitment and anti-tumor immunity. Recognize the role of non-immune agents in promoting tumor immunity in combination with cytokines, vaccines, and immune cell engagers. Define immunogenic cell death (ICD) and describe how combination approaches promote ICD and anti-tumor immunity. Explain the abscopal effect of local therapy. Describe how other agents can enhance immunotherapy.
Patient Selection, Management and Monitoring	Apply criteria for patient selection for IL-2 or interferon therapy. Identify contraindications to treatment with cytokines. Describe methods needed to safely monitor patients on high-dose IL-2 therapy. Describe criteria for patient selection for vaccine treatment. Identify contraindications to treatment with vaccine therapy. Describe patient selection criteria for immune cell engager therapies. Identify contraindications to immune cell engager therapies. Determine duration of treatment and when to assess patients for clinical response.
Management of Adverse Events	Recognize the type and severity of adverse events associated with cytokine, vaccine, and immune cell engager administration. Apply appropriate interventions to ameliorate toxicities associated with cytokines, vaccines, and immune cell engagers. Identify appropriate institutional and provider resources and procedures needed to manage cytokine-related toxicities. Recognize the importance of continuing education for high-dose cytokine delivery teams. Recognize the interactions between cytokines, vaccines, and immune cell engagers with other immunotherapy and non-immunotherapy cancer agents for causing unknown or unexpected adverse events.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Certificate in Cancer Immunotherapy Webseries, Module Five

Date of CE Release: July 7, 2021

Date of CE Expiration: July 7, 2023

Approximate Time to Complete: 90 minutes

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 75% or higher and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits^TM for physicians, 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

UAN: JA4008163-9999-21-141-H04-P / JA4008163-9999-21-141-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1—6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Relationship: Commercial Entity
Aaron	Brodersen	NA
Leisha	Emens	Consultant: Genentech, F Hoffman La Roche, Syndax, Lilly, AbbVie, Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; Contracted Research: Aduro Biotech, Astrazeneca, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Royalties: Elsevier
Umar	Farooq	Consultant: Kite Pharma, Inc
James	Gulley	NA
Tiffany	Klopp	NA
Jane	Kosirog-Glowcki	NA
Claire	Leischer	NA
Francesco	Marincola	Consulting: Calidi Biotechnologie
Scott	McGee-Plys	NA
Edwin	O'Sullivan	Ownership Interest: Aveo Oncology
Emily	Shepard	NA
Jill	Wall	NA

Method of Participation and Request for Credit
During the period 7/1/2021 through 7/1/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.